Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

GM-CSF protein reduces AD pathology, reverses memory loss: Study

GM-CSF protein reduces AD pathology, reverses memory loss: Study

MMV joins Pool for Open Innovation against neglected tropical diseases

MMV joins Pool for Open Innovation against neglected tropical diseases

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million

Taoist Tai Chi internal arts of health celebrates 40 years

Taoist Tai Chi internal arts of health celebrates 40 years

FDA issues formal response to Nephros' 510(k) application for hemodiafiltration system

FDA issues formal response to Nephros' 510(k) application for hemodiafiltration system

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver